Abstract | OBJECTIVE: METHODS: RESULTS: A total of 47 visit data points were recorded. The mean ± SD duration of followup of patients receiving abatacept was 19.1 ± 12.7 months (range 3-33 months). Analysis was limited to 18 months of followup (included 77% of all visits [36 of 47]). Four patients were started on antiviral prophylaxis for hepatitis B with the initiation of abatacept, while 4 patients were not. Among the 4 patients who received antiviral prophylaxis, RA improved as evidenced by a statistically significant decrease in DAS28-ESR scores, and none had reactivation of hepatitis B. In the 4 patients without antiviral prophylaxis, there was no significant decrease in the DAS28-ESR scores and all 4 experienced reactivation of hepatitis B. There were no adverse events other than the hepatitis B reactivation. CONCLUSION:
|
Authors | Paul S Kim, Gerald Y Ho, Pamela E Prete, Daniel E Furst |
Journal | Arthritis care & research
(Arthritis Care Res (Hoboken))
Vol. 64
Issue 8
Pg. 1265-8
(Aug 2012)
ISSN: 2151-4658 [Electronic] United States |
PMID | 22392695
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 by the American College of Rheumatology. |
Chemical References |
- Antirheumatic Agents
- Antiviral Agents
- Immunoconjugates
- Tumor Necrosis Factor-alpha
- Abatacept
|
Topics |
- Abatacept
- Aged
- Antirheumatic Agents
(administration & dosage, adverse effects)
- Antiviral Agents
(administration & dosage, adverse effects)
- Arthritis, Rheumatoid
(complications, drug therapy)
- Comorbidity
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepatitis B, Chronic
(complications, drug therapy)
- Humans
- Immunoconjugates
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Retrospective Studies
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|